PRESS RELEASE

Q2 2025 — Press release

Q2 2025PDF · 14 pages268 KB
- 1 -
News Release
____________________________________________________________________________
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial
Results
- 	Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter
2024 Both Nominally and Excluding the Impact of Foreign Exchange
o 	KEYTRUDA Sales Were $8.0 Billion, Growth of 9% Both Nominally and
Excluding the Impact of Foreign Exchange
o 	WINREVAIR Sales Were $336 Million
o 	Animal Health Sales Were $1.6 Billion, Growth of 11% Both Nominally and
Excluding the Impact of Foreign Exchange
o 	GARDASIL/GARDASIL 9 Sales Were $1.1 Billion, a Decline of 55% Both
Nominally and Excluding the Impact of Foreign Exchange
- 	GAAP EPS Was $1.76; Non-GAAP EPS Was $2.13; GAAP and Non-GAAP EPS Include
a Charge of $0.07 per Share for Closing of Hengrui Pharma License Agreement
- 	Announced Agreement To Acquire Verona Pharma and Its First-In-Class COPD
Maintenance Treatment for Adults, Ohtuvayre®;1 Transaction Expected To Close in
Fourth Quarter 2025
- 	Announced Positive Topline Results From First Two Phase 3 CORALreef Trials of
Enlicitide Decanoate for Treatment of Adults With Hyperlipidemia
- 	Received FDA Approval of ENFLONSIA for Prevention of RSV Lower Respiratory Tract
Disease in Infants Born During or Entering Their First RSV Season; CDC’s ACIP
Recommended ENFLONSIA for Prevention of RSV in Infants Younger Than 8 Months of
Age for Their First RSV Season
- 	Announced Multiyear Optimization Initiative Anticipated To Result in Approximately $3.0
Billion of Annual Cost Savings by the End of 2027, To Be Fully Reinvested Into Strategic
Growth Areas
- 	Full-Year 2025 Financial Outlook
o 	Narrows Expected Worldwide Sales Range To Be Between $64.3 Billion and
$65.3 Billion
o 	Narrows Expected Non-GAAP EPS Range To Be Between $8.87 and $8.97
o 	Outlook Does Not Include Anticipated Impact of the Announced Acquisition of
Verona Pharma
RAHWAY, N.J., July 29, 2025 – Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as
MSD outside the United States and Canada, today announced financial results for the second
quarter of 2025.
1 All trademarks are property of their respective owners.

-- 1 of 14 --

- 2 -
"Earlier this month, we were pleased to announce our pending acquisition of Verona
Pharma, which augments our portfolio and pipeline and is another example of acting decisively
when science and value align,” said Robert M. Davis, chairman and chief executive officer.
“Today, we announced a multiyear optimization initiative that will redirect investment and
resources from more mature areas of our business to our burgeoning array of new growth
drivers, further enable the transformation of our portfolio, and drive our next chapter of
productive, innovation-driven growth. With these actions, I am confident that we are well
positioned to generate near- and long-term value for our shareholders and, most importantly,
deliver for our patients.”
Financial Summary
*Refer to table on page 7.
For the second quarter of 2025, Generally Accepted Accounting Principles (GAAP)
earnings per share (EPS) assuming dilution was $1.76 and non-GAAP EPS was $2.13. GAAP
and non-GAAP EPS in the second quarter of 2025 include a charge of $0.07 per share for an
upfront payment to Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma) upon closing
of a license agreement. Non-GAAP EPS excludes acquisition- and divestiture-related costs,
costs related to restructuring programs, and income and losses from investments in equity
securities. Non-GAAP EPS in the second quarter of 2025 also excludes tax benefits primarily
resulting from favorable audit adjustments. Non-GAAP EPS in the second quarter of 2024 also
excludes a tax benefit due to a reduction in reserves for unrecognized income tax benefits,
resulting from the expiration of the statute of limitations for assessments related to the 2019
federal tax return year.
Year-to-date results can be found in the attached tables.
2 Net income attributable to the Company.
3 The Company is providing certain 2025 and 2024 non-GAAP information that excludes certain items because of the nature of
these items and the impact they have on the analysis of underlying business performance and trends. Management believes that
providing this information enhances investors’ understanding of the Company’s results because management uses non-GAAP
results to assess performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to
measure the performance of the Company along with other metrics. In addition, annual employee compensation, including senior
management’s compensation, is derived in part using a non-GAAP pretax income metric. This information should be considered in
addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the non-
GAAP adjustments, see Table 2a attached to this release.
$ in millions, except EPS amounts
Second Quarter
2025 	2024 	Change
Change Ex-
Exchange
Sales 	$15,806 	$16,112 	-2% 	-2%
GAAP net income2 	4,427 	5,455 	-19% 	-17%
Non-GAAP net income that excludes certain items2,3* 	5,366 	5,809 	-8% 	-6%
GAAP EPS 	1.76 	2.14 	-18% 	-16%
Non-GAAP EPS that excludes certain items3* 	2.13 	2.28 	-7% 	-5%

-- 2 of 14 --

- 3 -
Second-Quarter Sales Performance
The following table reflects sales of the Company’s top products and significant
performance drivers.
Second Quarter
$ in millions 	2025 	2024 	Change
Change Ex-
Exchange 	Commentary
Total Sales 	$15,806 	$16,112 	-2% 	-2%
Pharmaceutical 	14,050 	14,408 	-2% 	-3%
Decline primarily due to vaccines and
immunology, partially offset by growth
in oncology and cardiology.
KEYTRUDA 	7,956 	7,270 	9% 	9%
Growth driven by continued strong
global demand from metastatic
indications, including bladder,
endometrial and gastric cancers, and
increased global uptake in earlier-
stage indications, including triple-
negative breast cancer, renal cell
carcinoma (RCC) and cervical
cancer, as well as non-small cell lung
cancer in the U.S.
GARDASIL/GARDASIL 9 	1,126 	2,478 	-55% 	-55%
Decline primarily due to lower
demand in China. Excluding China,
sales declined 3%, or 4% excluding
impact of foreign exchange, reflecting
lower demand in Japan following a
national catch-up immunization
program, as well as timing of public-
sector purchases in certain
international markets. U.S. sales
increased 2% in the quarter.
JANUVIA/JANUMET 	623 	629 	-1% 	-
Decrease primarily attributable to
lower demand in China, impacts of
generic competition in most
international markets, and lower
demand in the U.S. due to
competitive pressure, which were
largely offset by higher net pricing in
the U.S.
PROQUAD, M-M-R II and
VARIVAX 	609 	617 	-1% 	-2%
Decrease primarily reflects lower U.S.
sales due to unfavorable VARIVAX
public-sector activity and M-M-R II
private-sector buy-out, partially offset
by partial replenishment of
PROQUAD doses borrowed from the
U.S. Centers for Disease Control and
Prevention (CDC) Pediatric Vaccine
Stockpile, and higher pricing.
BRIDION 	461 	455 	1% 	1%
Increase primarily due to higher
demand in the U.S., partially offset by
lower demand in most international
markets due to ongoing generic
competition.
Lynparza* 	370 	317 	17% 	15%
Growth primarily due to higher
demand in the U.S. and certain
international markets.
WINREVAIR 	336 	70 	N/M 	N/M
Growth reflects continued uptake
since second-quarter 2024 launch in
the U.S.

-- 3 of 14 --

- 4 -
Second Quarter
$ in millions 	2025 	2024 	Change
Change Ex-
Exchange 	Commentary
Lenvima* 	265 	249 	6% 	5%
Increase primarily due to higher sales
in the U.S. reflecting higher demand,
partially offset by lower pricing.
VAXNEUVANCE 	229 	189 	21% 	20%
Growth primarily due to favorable
public-sector activity in the U.S. and
increased demand in certain
international markets, partially offset
by lower demand in the U.S. and
Japan due to competitive pressure.
PREVYMIS 	228 	188 	21% 	20%
Growth primarily due to higher
demand in the U.S. and Europe,
partially offset by lower demand in
China due to generic competition.
WELIREG 	162 	126 	29% 	29%
Growth primarily driven by higher
demand in the U.S. and early launch
uptake in certain EU markets,
partially offset by lower pricing in the
U.S.
CAPVAXIVE 	129 	- 	- 	-
Represents continued uptake since
third-quarter 2024 launch in the U.S.
SIMPONI 	- 	172 	-100% 	-100%
Marketing rights in former territories
of the Company reverted to Johnson
& Johnson on Oct. 1, 2024.
Animal Health 	1,646 	1,482 	11% 	11%
Growth primarily due to higher
demand for Livestock products, as
well as inclusion of sales from Elanco
aqua business acquired in July 2024,
higher pricing and improved supply.
Livestock 	961 	837 	15% 	16%
Growth primarily driven by higher
demand across all species, as well as
inclusion of sales from Elanco aqua
business acquired in July 2024.
Companion Animal 	685 	645 	6% 	6%
Increase primarily driven by higher
pricing. Sales of BRAVECTO were
$335 million and $331 million in
current and prior year quarters,
respectively, which represents an
increase of 1%, both nominally and
excluding impact of foreign exchange.
Other Revenues** 	110 	222 	-50% 	-3%
Primarily due to unfavorable impact of
revenue-hedging activities.
*Alliance revenue for this product represents the Company’s share of profits, which are product sales net of cost of sales and
commercialization costs.
**Other revenues are comprised primarily of revenues from third-party manufacturing arrangements and miscellaneous corporate revenues,
including revenue-hedging activities.
N/M- Not meaningful.

-- 4 of 14 --

- 5 -
Second-Quarter Expense, EPS and Related Information
The table below presents selected expense information.
$ in millions 	GAAP
Acquisition-
and
Divestiture-
Related
Costs4
Restructuring
Costs
(Income)
Loss From
Investments
in Equity
Securities
Non-
GAAP3
Second Quarter 2025
Cost of sales 	$3,557 	$576 	$165 	$- 	$2,816
Selling, general and administrative 	2,649 	15 	1 	- 	2,633
Research and development 	4,048 	3 	53 	- 	3,992
Restructuring costs 	560 	- 	560 	- 	-
Other (income) expense, net 	(7) 	- 	- 	(61) 	54
Second Quarter 2024
Cost of sales 	$3,745 	$606 	$66 	$- 	$3,073
Selling, general and administrative 	2,739 	24 	31 	- 	2,684
Research and development 	3,500 	20 	- 	- 	3,480
Restructuring costs 	80 	- 	80 	- 	-
Other (income) expense, net 	42 	(17) 	- 	(49) 	108
GAAP Expense, EPS and Related Information
Gross margin was 77.5% for the second quarter of 2025 compared with 76.8% for the
second quarter of 2024. The increase was primarily due to the favorable impact of product mix,
partially offset by higher restructuring costs and inventory write-offs.
Selling, general and administrative (SG&A) expenses were $2.6 billion in the second
quarter of 2025, a decrease of 3% compared with the second quarter of 2024. The decrease
was primarily due to lower administrative, restructuring and promotional costs.
Research and development (R&D) expenses were $4.0 billion in the second quarter of
2025, an increase of 16% compared with the second quarter of 2024. The increase was
primarily due to a $200 million charge for an upfront payment made in the second quarter of
2025 for a license agreement with Hengrui Pharma, increased clinical development spending,
higher compensation and benefit costs, and higher restructuring costs.
Other (income) expense, net, was $7 million of income in the second quarter of 2025
compared with $42 million of expense in the second quarter of 2024.
The effective tax rate of 11.4% for the second quarter of 2025 includes a 2.9 percentage
point favorable impact due to tax benefits primarily resulting from favorable audit adjustments.
GAAP EPS was $1.76 for the second quarter of 2025 compared with $2.14 for the
second quarter of 2024. The decrease reflects increased operating expenses driven by higher
4 Reflects expenses related to business combinations, including the amortization of intangible assets, intangible asset impairment
charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent
consideration. Also includes integration, transaction and certain other costs associated with acquisitions and divestitures, as well
as amortization of intangible assets related to collaborations and licensing arrangements.

-- 5 of 14 --

- 6 -
restructuring costs and research and development spending, a charge related to the closing of a
license agreement with Hengrui Pharma, unfavorable tax impacts, and the unfavorable impact
of foreign exchange.
Non-GAAP Expense, EPS and Related Information
Non-GAAP gross margin was 82.2% for the second quarter of 2025 compared with
80.9% for the second quarter of 2024. The increase was primarily due to the favorable impact of
product mix, partially offset by higher inventory write-offs.
Non-GAAP SG&A expenses were $2.6 billion in the second quarter of 2025, a decrease
of 2% compared with the second quarter of 2024. The decrease was primarily due to lower
administrative and promotional costs.
Non-GAAP R&D expenses were $4.0 billion in the second quarter of 2025, an increase
of 15% compared with the second quarter of 2024. The increase was primarily due to a $200
million charge for an upfront payment made in the second quarter of 2025 for a license
agreement with Hengrui Pharma, increased clinical development spending, and higher
compensation and benefit costs.
Non-GAAP other (income) expense, net, was $54 million of expense in the second
quarter of 2025 compared with $108 million of expense in the second quarter of 2024.
The non-GAAP effective tax rate was 15.0% for the second quarter of 2025.
Non-GAAP EPS was $2.13 for the second quarter of 2025 compared with $2.28 for the
second quarter of 2024. The decrease reflects increased operating expenses driven by higher
research and development spending, a charge related to the closing of a license agreement
with Hengrui Pharma, and the unfavorable impact of foreign exchange.

-- 6 of 14 --

- 7 -
A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that
follows.
Planned Acquisition of Verona Pharma
On July 9, 2025, the Company furthered its science-led business development strategy
by announcing an agreement under which the Company, through a subsidiary, will acquire
Verona Pharma plc (Verona Pharma) for $107 per American Depository Share, each of which
represents eight Verona Pharma ordinary shares, for a total transaction value of approximately
$10 billion. Through the acquisition, the Company will add Ohtuvayre, a first-in-class selective
dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary
pipeline and portfolio.
The U.S. Food and Drug Administration (FDA) approved Ohtuvayre in June 2024 for the
maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. It is
the first novel inhaled mechanism for the treatment of COPD in more than 20 years. The
transaction is anticipated to close in the fourth quarter of 2025.
Pipeline and Portfolio Highlights
In the second quarter, the Company continued to advance its broad and diverse pipeline
with multiple regulatory and clinical milestones.
In oncology, the FDA approved KEYTRUDA as part of a therapy regimen for the
treatment of certain adult patients with resectable locally advanced head and neck squamous
cell carcinoma (HNSCC), based on results from the Phase 3 KEYNOTE-689 trial. This approval
5 Includes the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the
non-GAAP adjustments for both periods presented. Amount in the second quarter of 2025 also includes a $146 million benefit
primarily resulting from favorable audit adjustments. Amount in the second quarter of 2024 also includes a $259 million benefit due
to a reduction in reserves for unrecognized income tax benefits resulting from the expiration of the statute of limitations for
assessments related to the 2019 federal tax return year.
Second Quarter
$ in millions, except EPS amounts 	2025 	2024
EPS
GAAP EPS 	$1.76 	$2.14
Difference 	0.37 	0.14
Non-GAAP EPS that excludes items listed below3 	$2.13 	$2.28
Net Income
GAAP net income2 	$4,427 	$5,455
Difference 	939 	354
Non-GAAP net income that excludes items listed below2,3 	$5,366 	$5,809
Excluded Items:
Acquisition- and divestiture-related costs4 	$594 	$633
Restructuring costs 	779 	177
Income from investments in equity securities 	(61) 	(49)
Decrease to net income before taxes 	1,312 	761
Estimated income tax (benefit) expense5 	(373) 	(407)
Decrease to net income 	$939 	$354

-- 7 of 14 --

- 8 -
is the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced
HNSCC whose tumors express PD-L1 (CPS ≥1). In addition, the Ministry of Health, Labor and
Welfare (MHLW) in Japan approved WELIREG as monotherapy for the treatment of adults with
von Hippel-Lindau (VHL) disease-associated tumors, and for adults with unresectable or
metastatic RCC that has progressed after chemotherapy.
At the 2025 American Society of Clinical Oncology Annual Meeting, the Company
announced new research across more than 25 types of cancer in multiple treatment settings.
Data were presented for several candidates, including MK-1084, an investigational oral
selective KRAS G12C inhibitor, and from the Company’s pipeline of antibody-drug conjugates
(ADCs). The Company also presented data from Phase 3 trials evaluating new combination
regimens with KEYTRUDA, and longer-term data for studies of KEYTRUDA and WELIREG,
with the KEYTRUDA studies including people with earlier stages of cancer.
The Company announced results from the Phase 3 KEYNOTE-B96 trial (also known as
ENGOT-ov65) evaluating KEYTRUDA plus chemotherapy, which met its primary endpoint of
progression-free survival (PFS) for the treatment of patients with platinum-resistant recurrent
ovarian cancer whose tumors express PD-L1 and in all comers, as well as a secondary
endpoint of overall survival (OS) in patients whose tumors express PD-L1. In addition, a pre-
specified interim analysis of the Phase 3 KEYNOTE-937 study found that compared to placebo,
KEYTRUDA did not show a statistically significant improvement in the primary endpoint of
recurrence-free survival for certain patients with hepatocellular carcinoma. Also, a pre-specified
interim analysis of the Phase 3 LEAP-014 trial found that KEYTRUDA plus Lenvima, in
combination with platinum-based chemotherapy, did not show a statistically significant
improvement in its primary endpoint of OS compared to KEYTRUDA plus chemotherapy for the
first-line treatment of patients with metastatic esophageal squamous cell carcinoma (ESCC).
In vaccines and infectious diseases, the Company received FDA approval of
ENFLONSIA for the prevention of respiratory syncytial virus (RSV) lower respiratory tract
disease in newborns and infants who are born during or entering their first RSV season.
ENFLONSIA is the first and only RSV preventive option administered to infants using the same
dose regardless of weight. The CDC’s Advisory Committee on Immunization Practices (ACIP)
also recommended ENFLONSIA for the prevention of RSV in infants younger than 8 months of
age born during or entering their first RSV season. In addition, the Company announced
initiation of the MOBILIZE-1 Phase 3 trial evaluating V181, an investigational single-dose
quadrivalent vaccine for the prevention of dengue disease.
In addition, the FDA accepted a New Drug Application (NDA) for doravirine/islatravir, an
investigational, once-daily, oral, two-drug regimen for the treatment of adults with virologically
suppressed HIV-1 based on the Phase 3 MK-8591A-051 and MK-8591A-052 trials. The FDA set
a Prescription Drug User Fee Act (PDUFA) date of April 28, 2026. The Company also
announced the initiation of the EXPrESSIVE Phase 3 trials for MK-8527, its investigational
once-monthly oral candidate for HIV pre-exposure prophylaxis (PrEP).

-- 8 of 14 --

- 9 -
In cardiovascular disease, the Company announced positive topline results from Phase
3 CORALreef HeFH and CORALreef AddOn, the first two of three Phase 3 clinical trials
evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein
convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for the treatment of adults
with hyperlipidemia already on lipid-lowering therapies, including at least a statin. In both trials,
enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density
lipoprotein cholesterol. If approved, it would be the first marketed oral PCSK9 inhibitor.
In addition, the FDA granted priority review for a new supplemental Biologics License
Application for WINREVAIR seeking approval to update the U.S. product label based on
compelling results from the Phase 3 ZENITH trial. The FDA has set a PDUFA date of Oct. 25,
2025. The Company also provided an update on the Phase 3 HYPERION study evaluating
WINREVAIR in recently diagnosed adults with pulmonary arterial hypertension (PAH). In the
study, WINREVAIR added on top of background therapy within 12 months after initial diagnosis
of PAH demonstrated a statistically significant and clinically meaningful reduction in the risk of
clinical worsening events when compared to placebo. Further, the MHLW in Japan approved
sotatercept for the treatment of adults with PAH under the trademark AIRWIN. It is the first
activin signaling inhibitor therapy for PAH approved in Japan.
In the Animal Health business, the FDA approved BRAVECTO QUANTUM, an injectable
formulation of BRAVECTO for dogs for the treatment and persistent killing of fleas and ticks. In
addition, the European Commission (EC) approved NUMELVI tablets for dogs, a once-daily,
second-generation Janus kinase (JAK) inhibitor, indicated for the treatment of pruritus
associated with allergic dermatitis including atopic dermatitis and treatment of clinical
manifestations of atopic dermatitis.
Notable recent news releases on the Company’s pipeline and portfolio are provided in
the table that follows. Visit the News Releases section of the Company’s website to read the
releases*.
Oncology
FDA Approved KEYTRUDA for PD-L1+ Resectable Locally Advanced HNSCC as
Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy
With or Without Cisplatin Then as a Single Agent; Based on Results From Phase 3
KEYNOTE-689 Trial
FDA Approved WELIREG for Treatment of Adults and Pediatric Patients 12 Years and
Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or
Paraganglioma; Based on Results From Phase 2 LITESPARK-015 Clinical Trial
Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of PFS in Patients With Platinum-
Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
KEYTRUDA Plus Trodelvy Reduced Risk of Disease Progression or Death by 35% Versus
KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast
Cancer; Based on Results From Phase 3 ASCENT-04/KEYNOTE-D19 Trial
MK-1084, an Investigational KRAS G12C Inhibitor, Showed Antitumor Activity in Phase 1
Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer
Whose Tumors Harbor KRAS G12C Mutations
Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed
Promising Antitumor Activity, Including Complete Response Rate, in Patients With
Relapsed/Refractory Diffuse Large B-Cell Lymphoma; Based on Results From Phase 2
WaveLINE-003 Trial

-- 9 of 14 --

- 10 -
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients With
Pretreated Metastatic Castration-Resistant Prostate Cancer
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients
With Pretreated Advanced or Metastatic ESCC
Vaccines and
Infectious Diseases
FDA Approved ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in
Infants Born During or Entering Their First RSV Season; Based on Results From Phase
2b/3 CLEVER Trial
ACIP Recommended Use of ENFLONSIA for Prevention of RSV Lower Respiratory Tract
Disease in Infants Younger Than 8 Months of Age Born During or Entering Their First RSV
Season
FDA Accepted NDA for Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-
Drug Regimen for Treatment of Adults With Virologically Suppressed HIV-1; Based on
Results From Phase 3 MK-8591A-051 and MK-8591A-052 Trials; FDA Set PDUFA Date
of April 28, 2026
EXPrESSIVE Phase 3 Trials Initiated for Investigational Once-Monthly HIV Prevention Pill,
MK-8527
The Company Initiated MOBILIZE-1 Phase 3 Study Evaluating Dengue Vaccine
Candidate
Cardiovascular
FDA Granted Priority Review for WINREVAIR to Update Label Based on Results From
ZENITH Trial; FDA Set PDUFA Date of Oct. 25, 2025
The Company Announced Positive Topline Results From First Two Phase 3 CORALreef
Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
Phase 3 HYPERION Study of WINREVAIR Met Primary Endpoint in Recently Diagnosed
Adults With PAH
Animal Health FDA Approved BRAVECTO QUANTUM
EC Approved NUMELVI Tablets for Dogs
*References to the Company’s name in the above news release titles have been modified for the purpose of this announcement.
New Multiyear Optimization Initiative, Which Includes a Restructuring Program
The Company launched a new multiyear optimization initiative to enable the
transformation of its portfolio by generating an expected $3.0 billion in annual cost savings from
productivity actions, which will be fully reinvested to support new product launches and its
pipeline across multiple therapeutic areas.
In July 2025, as part of this initiative, the Company approved a new restructuring
program, in which it expects to eliminate certain administrative, sales and R&D positions. The
Company will, however, continue to hire employees into new roles across strategic growth
areas of the business. In addition, the Company will reduce its global real estate footprint and
continue to optimize its manufacturing network, aligning the geography of its global
manufacturing to its customers and reflecting changes in the Company’s business.
The Company anticipates cumulative pretax costs related to the program to be
approximately $3.0 billion. For the second quarter of 2025, the Company recorded charges in its
GAAP results of $649 million related to this restructuring program.
The Company expects the actions under the restructuring program to result in annual
cost savings of approximately $1.7 billion, which will be substantially realized by the end of
2027. This restructuring program is part of the multiyear optimization initiative expected to
achieve $3.0 billion in annual cost savings by the end of 2027.

-- 10 of 14 --

- 11 -
Manufacturing and R&D Investment
The Company continued to make long-term investments in its U.S. manufacturing and
R&D capabilities. This includes the start of construction for a $1.0 billion, 470,000-square-foot
state-of-the-art biologics center of excellence in Wilmington, Delaware, which will serve as a
launch and commercial production facility and the primary U.S. manufacturing site for
KEYTRUDA. In addition, the Company announced an $895 million expansion of its Animal
Health manufacturing facility in De Soto, Kansas; the 200,000-square-foot facility will increase
capacity for Animal Health vaccines and biologic products.
Full-Year 2025 Financial Outlook
The following table summarizes the Company’s full-year financial outlook.
Full Year 2025
Updated 	Prior
Sales* 	$64.3 billion to $65.3 billion 	$64.1 billion to $65.6 billion
Non-GAAP Gross margin3 	Approximately 82% 	Approximately 82%
Non-GAAP Operating expenses3** 	$25.6 billion to $26.4 billion 	$25.6 billion to $26.6 billion
Non-GAAP Other (income) expense, net3 	$300 million to $400 million expense 	$300 million to $400 million expense
Non-GAAP Effective tax rate3 	15.0% to 16.0% 	15.5% to 16.5%
Non-GAAP EPS3*** 	$8.87 to $8.97 	$8.82 to $8.97
Share count (assuming dilution) 	Approximately 2.51 billion 	Approximately 2.51 billion
*The Company does not have any non-GAAP adjustments to sales.
**Includes one-time R&D charges of $300 million for a milestone payment to LaNova Medicines Ltd. (LaNova) associated with the technology
transfer for MK-2010 expected to be recorded in the third quarter of 2025 and $200 million for the upfront payment for the license agreement
completed with Hengrui Pharma in the second quarter of 2025.
Outlook does not assume any additional significant potential business development transactions.
***Includes one-time charges totaling $0.16 per share associated with the payment for the LaNova technology transfer for MK-2010 and
upfront payment to Hengrui Pharma.
The Company has not provided a reconciliation of forward-looking non-GAAP gross
margin, non-GAAP operating expenses, non-GAAP other (income) expense, net, non-GAAP
effective tax rate and non-GAAP EPS to the most directly comparable GAAP measures, given it
cannot predict with reasonable certainty the amounts necessary for such a reconciliation,
including intangible asset impairment charges, legal settlements, and income and losses from
investments in equity securities either owned directly or through ownership interests in
investment funds, without unreasonable effort. These items are inherently difficult to forecast
and could have a significant impact on the Company’s future GAAP results.
The Company now expects full-year 2025 sales to be between $64.3 billion and $65.3
billion, including a revised negative impact of foreign exchange of approximately 0.5% at mid-
July 2025 exchange rates.
The Company now expects its full-year non-GAAP effective income tax rate to be
between 15.0% and 16.0%.
The Company now expects its full-year non-GAAP EPS to be between $8.87 and $8.97,
including a revised negative impact of foreign exchange of approximately $0.15 per share. This
revised non-GAAP EPS range continues to reflect the impacts of a one-time charge of $200

-- 11 of 14 --

- 12 -
million (recorded in the second quarter of 2025) for an upfront payment made in connection with
the closing of a license agreement with Hengrui Pharma and the one-time charge of $300
million (to be recorded in the third quarter of 2025) related to a payment to LaNova for the
completion of the technology transfer for MK-2010, which will impact EPS by approximately
$0.16 in the aggregate. In 2024, non-GAAP EPS of $7.65 was negatively impacted by a net
charge of $1.28 per share related to certain asset acquisitions, licensing agreements and
collaborations.
The financial outlook does not include the anticipated impact of the announced
acquisition of Verona Pharma.
Consistent with past practice, the financial outlook does not assume additional
significant potential business development transactions.
The $200 million of costs previously included in the Company’s financial outlook related
to the impact of tariffs is unchanged pending the outcome of additional potential government
actions.
Earnings Conference Call
Investors, journalists and the general public may access a live audio webcast of the call
on Tuesday, July 29, at 9 a.m. ET via this weblink. A replay of the webcast, along with the sales
and earnings news release, supplemental financial disclosures and slides highlighting the
results, will be available on the Company’s website.
All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Free)
or (517) 308-9448 and using the access code 9818590.
About Our Company
At Merck & Co., Inc., Rahway, N.J., USA, known as MSD outside of the United States
and Canada, we are unified around our purpose: We use the power of leading-edge science to
save and improve lives around the world. For more than 130 years, we have brought hope to
humanity through the development of important medicines and vaccines. We aspire to be the
premier research-intensive biopharmaceutical company in the world – and today, we are at the
forefront of research to deliver innovative health solutions that advance the prevention and
treatment of diseases in people and animals. We foster a diverse and inclusive global workforce
and operate responsibly every day to enable a safe, sustainable and healthy future for all
people and communities.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “Company”) includes
“forward-looking statements” within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. These statements are based upon the current
beliefs and expectations of the Company’s management and are subject to significant risks and
uncertainties. There can be no guarantees with respect to pipeline candidates that the

-- 12 of 14 --

- 13 -
candidates will receive the necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties
materialize, actual results may differ materially from those set forth in the forward-looking
statements.
Risks and uncertainties include but are not limited to, general industry conditions and
competition; general economic factors, including interest rate and currency exchange rate
fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approval; the Company’s ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk; dependence on the effectiveness of the
Company’s patents and other protections for innovative products; and the exposure to litigation,
including patent litigation, and/or regulatory actions.
The Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise. Additional factors
that could cause results to differ materially from those described in the forward-looking
statements can be found in the Company’s Annual Report on Form 10-K for the year ended
December 31, 2024 and the Company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Appendix
Generic product names are provided below.
Pharmaceutical
BRIDION (sugammadex)
CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine)
ENFLONSIA (clesrovimab-cfor)
GARDASIL (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine,
Recombinant)
GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant)
JANUMET (sitagliptin and metformin HCl)
JANUVIA (sitagliptin)
KEYTRUDA (pembrolizumab)
Lenvima (lenvatinib)
Lynparza (olaparib)
M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live)
PREVYMIS (letermovir)
PROQUAD (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)
SIMPONI (golimumab)
VARIVAX (Varicella Virus Vaccine Live)
VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine)

-- 13 of 14 --

- 14 -
WELIREG (belzutifan)
WINREVAIR (sotatercept-csrk)
Animal Health
BRAVECTO (fluralaner)
BRAVECTO QUANTUM (fluralaner for extended-release injectable suspension)
NUMELVI (atinvicitinib)
###
Media Contacts: 	Investor Contacts:
Michael Levey
michael.levey@msd.com
Johanna Herrmann
johanna.herrmann@msd.com
Peter Dannenbaum
(732) 594-1579
Steven Graziano
(732) 594-1583

-- 14 of 14 --